文献速递胰腺与胆道疾病消化内镜消化道肿瘤与早癌

EUS或ERCP支架置入用于胰腺癌原发性胆道减压:一项随机试验(附视频)

Stent placement by EUS or ERCP for primary biliary decompression in pancreatic cancer: a randomized trial (with videos).
PubMed 文献 · Gastrointest Endosc · 2018-03-21

单中心、单盲随机试验比较EUS-BD与ERCP作为胰腺癌远端胆道梗阻的一线治疗,EUS-BD组33例、ERCP组34例;不良事件发生率分别为21.2%与14.7%(风险比0.69,95%CI 0.24-1.97,P=0.49),技术成功、治疗成功及再干预率均无显著差异。

要点

  • EUS-BD组不良事件21.2%,ERCP组14.7%,风险比0.69(95%CI 0.24-1.97,P=0.49),无操作相关死亡。
  • 技术成功EUS-BD组90.9% vs ERCP组94.1%,治疗成功97% vs 91.2%,再干预3.0% vs 2.9%,均无显著差异。
  • 作者认为EUS-BD可作为胰腺癌原发性胆道减压中ERCP的实用替代方案。

核心结论

  • 作者认为,鉴于不良事件与治疗结局相似,EUS-BD是胰腺癌原发性胆道减压中ERCP的实用替代方案。

研究设计与样本

  • 单中心、单盲随机试验,EUS-BD组33例、ERCP组34例,随访至死亡或至少6个月(临床试验注册号NCT03054987)。

主要发现

  • 不良事件发生率EUS-BD组21.2%(其中6.1%为中度严重程度,其余为轻度)vs ERCP组14.7%(其中5.9%为中度严重程度,其余为轻度),风险比0.69(95%CI 0.24-1.97,P=0.49),无操作相关死亡。
  • 技术成功率EUS-BD组90.9% vs ERCP组94.1%(P=0.67);治疗成功率EUS-BD组97% vs ERCP组91.2%(P=0.61);再干预率EUS-BD组3.0% vs ERCP组2.9%(P=0.99),均无显著差异。
  • 后续胰十二指肠切除术EUS-BD组33例中5例(15.2%)vs ERCP组34例中5例(14.7%)(P=0.99),内镜干预未妨碍后续手术。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Studies on EUS-guided transmural biliary drainage (EUS-BD) have evaluated its efficacy as a rescue technique after failed ERCP. We performed a single-center, single-blind, randomized trial to compare EUS-BD and ERCP as primary treatment for distal biliary obstruction in pancreatic cancer. METHODS: Patients underwent EUS-BD (n = 33) or ERCP (n = 34). The primary endpoint was the rate of adverse events. Secondary endpoints were technical success, treatment success (defined as decline in serum bilirubin by 50% at a 2-week follow-up), reinterventions, and intraoperative technical outcome, when applicable. Follow-up was until death or a minimum of 6 months. RESULTS: The rates of adverse events were 21.2% (6.1% moderate severity; others mild severity) in the EUS-BD group and 14.7% (5.9% moderate severity; others mild severity) in the ERCP group (risk ratio, .69; 95% confidence interval, .24-1.97; P = .49). There were no procedure-related deaths. There was no significant difference in the rates of technical success (90.9% vs 94.1%, P = .67), treatment success (97% vs 91.2%, P = .61), or reinterventions (3.0% vs 2.9%, P = .99) between EUS-BD and ERCP cohorts, respectively. The endoscopic interventions did not impede subsequent pancreaticoduodenectomy that was performed in 5 of 33 patients (15.2%) in the EUS-BD and 5 of 34 patients (14.7%) in the ERCP group (P = .99). CONCLUSIONS: Given the similar rates of adverse events and treatment outcomes in this randomized trial, EUS-BD is a practical alternative to ERCP for primary biliary decompression in pancreatic cancer. (Clinical trial registration number: NCT03054987.).

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Bang JY, Navaneethan U, Hasan M, et al. Stent placement by EUS or ERCP for primary biliary decompression in pancreatic cancer: a randomized trial (with videos). Gastrointest Endosc. 2018. PMID: 29574126. doi:10.1016/j.gie.2018.03.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。